VORVor Biopharma Inc.

Nasdaq vorbio.com


$ 1.69 $ -0.10 (-5.52 %)    

Friday, 10-May-2024 15:59:56 EDT
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 1.71
$ 1.76
$ 1.69 x 300
$ 0.00 x 0
$ 1.66 - $ 1.76
$ 1.62 - $ 5.70
249,880
na
116.33M
$ 0.59
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-20-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-23-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-14-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 03-25-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wedbush-reiterates-outperform-on-vor-biopharma-maintains-11-price-target

Wedbush analyst David Nierengarten reiterates Vor Biopharma (NASDAQ:VOR) with a Outperform and maintains $11 price target.

 vor-biopharma-q1-2024-gaap-eps-045-misses-037-estimate

Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.37...

 wedbush-reiterates-outperform-on-vor-biopharma-maintains-11-price-target

Wedbush analyst David Nierengarten reiterates Vor Biopharma (NASDAQ:VOR) with a Outperform and maintains $11 price target.

 jmp-securities-reiterates-market-outperform-on-vor-biopharma-maintains-12-price-target

JMP Securities analyst Silvan Tuerkcan reiterates Vor Biopharma (NASDAQ:VOR) with a Market Outperform and maintains $12 pric...

 stifel-maintains-buy-on-vor-biopharma-lowers-price-target-to-12

Stifel analyst Stephen Willey maintains Vor Biopharma (NASDAQ:VOR) with a Buy and lowers the price target from $15 to $12.

 wedbush-reiterates-outperform-on-vor-biopharma-maintains-11-price-target

Wedbush analyst David Nierengarten reiterates Vor Biopharma (NASDAQ:VOR) with a Outperform and maintains $11 price target.

 oppenheimer-reiterates-outperform-on-vor-biopharma-lowers-price-target-to-15

Oppenheimer analyst Matthew Biegler reiterates Vor Biopharma (NASDAQ:VOR) with a Outperform and lowers the price target from...

 hc-wainwright--co-reiterates-buy-on-vor-biopharma-maintains-175-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Vor Biopharma (NASDAQ:VOR) with a Buy and maintains $17.5 ...

 vor-biopharma-q4-2023-gaap-eps-039-beats-051-estimate

Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.51) ...

 wedbush-reiterates-outperform-on-vor-biopharma-maintains-11-price-target

Wedbush analyst David Nierengarten reiterates Vor Biopharma (NASDAQ:VOR) with a Outperform and maintains $11 price target.

 vor-bio-presents-data-update-on-trem-cel-at-hsct-conference-primary-neutrophil-engraftment-of-trem-cel-achieved-in-all-seven-patients-treated-to-date

Primary neutrophil engraftment of trem-cel achieved in all seven patients treated to date All three patients receiving multiple...

 vor-biopharma-q3-eps-049-misses-047-estimate

Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.47...

 multiple-clinical-and-preclinical-presentations-at-ash-2023-highlight-vor-bios-novel-ehsc-and-car-t-platform

Three oral and two poster presentations accepted by ASH Company to host call featuring Sarah K. Tasian, MD, Associate Professor...

 stocks-that-hit-52-week-lows-on-tuesday

  On Tuesday, 647 companies set new 52-week lows.

 stocks-that-hit-52-week-lows-on-thursday

  During the session on Thursday, 461 stocks hit new 52-week lows.

 stocks-that-hit-52-week-lows-on-tuesday

  During Tuesday's session, 275 companies made new 52-week lows.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION